Sign In
Buy ATHA
$6.61
+0 (+0%)
At Close: Apr 14, 2026
Athira Pharma, Inc. (ATHA) Upgraded to Buy: Here's What You Should Know
12:46pm, Thursday, 22'nd Apr 2021
Athira Pharma, Inc. (ATHA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Athira Pharma to Participate in Panel Discussion at Sachs 4th Annual Neuroscience Innovation Forum
07:00am, Wednesday, 21'st Apr 2021
BOTHELL, Wash., April 21, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health
Athira Pharma to Host Educational Webinar on Targeting HGF/MET: A Naturally Occurring Neuronal Repair Pathway
07:00am, Thursday, 08'th Apr 2021
BOTHELL, Wash., April 08, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health
Athira Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights
04:02pm, Thursday, 25'th Mar 2021
– LIFT-AD and ACT-AD studies evaluating ATH-1017, a once-daily investigational drug for the treatment of mild-to-moderate Alzheimer's disease, actively enrolling patients –
Athira Pharma to Present at Stifel's 3rd Annual CNS Conference
07:00am, Wednesday, 24'th Mar 2021
BOTHELL, Wash., March 24, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health
U.S. IPO Week Ahead: The Spring IPO Market Starts To Thaw In An 8 IPO Week
08:25am, Saturday, 13'th Mar 2021
The IPO market starts to pick back up with eight IPOs scheduled to raise $2.2 billion in the week ahead. Street research is expected for one company on Sunday, 3/14.
Athira Pharma to Present at H.C. Wainwright & Co. Global Life Sciences Conference
07:00am, Tuesday, 02'nd Mar 2021
BOTHELL, Wash., March 02, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health
3 Net-Net Working Capital Stocks
11:21am, Tuesday, 16'th Feb 2021
There are some investors who purchase stocks that are trading below their liquidation value because they believe they can make impressive gains out of their investments after the market has reassessed
Athira Pharma Announces Exercise of Underwriters' Option to Purchase Additional Shares
04:05pm, Wednesday, 10'th Feb 2021
BOTHELL, Wash., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc., (Nasdaq: ATHA) (“Athira”), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore n
Notable Insider Buys Seen In The Past Week: Green Brick, Intel, Teledyne And More
11:10am, Saturday, 30'th Jan 2021
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying ca
Why Athira Pharma Stock Dropped Today
05:50pm, Thursday, 21'st Jan 2021
The clinical-stage biopharma company announced the pricing of a public stock offering.
Athira Pharma Announces Pricing of Public Offering of Common Stock
07:35pm, Wednesday, 20'th Jan 2021
BOTHELL, Wash., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc., (Nasdaq: ATHA) (“Athira”), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore n
Athira Pharma Announces Proposed Public Offering of Common Stock
07:59am, Tuesday, 19'th Jan 2021
BOTHELL, Wash., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc., (Nasdaq: ATHA) (“Athira”), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore n
Athira: Early Stage Alzheimer's Therapeutics With An Interesting Approach
12:54pm, Monday, 11'th Jan 2021
Athira is a recent IPO with early but interesting data in AD. They will provide data from a potentially pivotal phase 2/3 trial in end-2022.
Athira Pharma to Present at the 39th Annual J.P. Morgan Healthcare Conference
07:30am, Thursday, 07'th Jan 2021
SEATTLE, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and sto
